Enzymatica AB: Complete article from COLDPREV I study published - strengthens documentation for ColdZyme

2017-10-18

News
Lund 18 October 2017

Complete article from COLDPREV I study published - strengthens documentation for ColdZyme

Enzymatica is presenting the recently published complete article from the COLDPREV I study in the Open Journal of Respiratory Diseases (OJRD). The double-blind placebo-controlled study evaluated ColdZyme® Mouth Spray for experimentally induced colds in healthy volunteers. The study results indicate that ColdZyme significantly reduces viral load and reduces the number of sick days with common cold symptoms.

The study was a pilot study conducted by the Department of Otorhinolaryngology (Ear, Nose and Throat) at Skåne University Hospital, and was previously published as both an abstract and a poster. In this randomised, double-blind placebo-controlled study, 46 subjects were inoculated (infected) with rhinovirus (cold virus). The results show a statistically significant difference between ColdZyme and placebo in reduction of both viral load (quantity of virus) in the throat (-99%) and number of days with common cold symptoms (-54%) from 6.5 to 3 days.

  • The very interesting study results have provided us with valuable information that will aid in the design of future follow-up studies of ColdZyme," says Fredrik Lindberg, CEO of Enzymatica.

ColdZyme Mouth Spray is a CE-marked medical device, with the intended use of reducing the risk of colds or reducing the disease period when early symptoms are present by creating a protective barrier in the mouth and throat.

      The analysis and graph are based on the number of people who were confirmed to be infected with the virus, or those who demonstrated symptoms.
Link to the complete article: https://doi.org/10.4236/ojrd.2017.74013

 For more information, please contact:

Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email: fredrik.lindberg@enzymatica.com   

About Enzymatica AB

Enzymatica AB is a life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The Company's first product is ColdZyme® Mouth Spray, which can prevent colds and reduce the duration of disease. The product has been launched in around ten markets. The strategy is to continue to grow by strengthening the Company's position in existing markets and expanding into new geographic markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North. For more information please visit: www.enzymatica.se.  

Related documents